Journal of Health and Rehabilitation Research 2791-156X JHRR

For contributions to JHRR, contact at email: editor@jhrlmc.com

Narrative Review

The Impact of Catechins, Capsaicin, and Gingerol in Managing Diabetes and Reducing the Risk of Atherosclerosis

Muhammad Hamza[1]*, Ghulam Fatima[2], Rubab Sana[3], Saba Ghafar[1], Ali Hamza[4], Muhammad Tahir Habib[5], Hunza Fatima[6], Maryam Latif[7], Hafiza Iqra Akram[1]

[1]Department of Nutritional Sciences, Government College University Faisalabad, Pakistan.
[2]Department of Zoology, Ghazi University, Dera Ghazi Khan, Pakistan.
[3]Allama Iqbal Medical College, Lahore, Pakistan.
[4]Department of Food Science and Technology, Muhammad Nawaz Sharif University of Agriculture, Multan, Pakistan.
[5]Department of Human Nutrition and Dietetics, Muhammad Nawaz Sharif University of Agriculture, Multan, Pakistan.
[6]Department of Home Economics, University of Agriculture Faisalabad, Pakistan.
[7]Department of Home Economics, Punjab University, Lahore, Pakistan.
Corresponding Author: Muhammad Hamza; Email: muhammadhamza6171@gmail.com

Conflict of Interest: None.

*Hamza M., et al. (2024). 4(1): **DOI**: https://doi.org/10.61919/jhrr.v4i1.529*

ABSTRACT

Background: Diabetes mellitus and atherosclerosis are significant contributors to global morbidity and mortality, with their prevalence escalating alongside the increasing incidence of obesity and sedentary lifestyles. Traditional therapeutic approaches have had limited success in fully managing these conditions, prompting interest in natural compounds such as capsaicin and gingerol. These compounds have been identified for their potential therapeutic effects, including anti-inflammatory, antioxidant, and metabolic regulatory properties.

Objective: This review aims to critically assess the impact of capsaicin and gingerol on the management of diabetes and atherosclerosis, highlighting their mechanisms of action, therapeutic potential, and clinical applications.

Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, Web of Science, and Google Scholar, focusing on studies that evaluated the effects of capsaicin and gingerol on diabetes and atherosclerosis. The search strategy incorporated a combination of keywords and MeSH terms related to the compounds and diseases of interest. Studies were selected based on predefined inclusion and exclusion criteria, with data extraction and quality assessment conducted according to standardized protocols.

Results: The review synthesized evidence from both animal models and human clinical trials, demonstrating that capsaicin and gingerol exhibit significant potential in improving metabolic health, reducing inflammation, and mitigating the risk factors associated with diabetes and atherosclerosis. Capsaicin was found to enhance weight management and cardiovascular health through mechanisms involving the sympathetic nervous system and TRPV1 activation. Gingerol showed potent anti-inflammatory effects and improved glucose and lipid metabolism. However, the clinical applicability of these findings requires further investigation to determine optimal dosages and long-term effects.

Conclusion: Capsaicin and gingerol present promising natural therapeutic options for the management of diabetes and atherosclerosis, with potential benefits extending beyond traditional treatment modalities. Further clinical trials are necessary to fully elucidate their therapeutic potential and integrate them into clinical practice.

Keywords: Capsaicin, Gingerol, Diabetes Mellitus, Atherosclerosis, Natural Compounds, Metabolic Health, Anti-inflammatory, Antioxidant, TRPV1, Cardiovascular Health.

INTRODUCTION

Diabetes mellitus (DM), a chronic metabolic disorder characterized by persistent hyperglycemia, arises either due to an insulin deficiency or impaired insulin function, positioning it as a significant public health issue with an escalating global prevalence. Forecasts suggest that by 2045, the diabetic population will surge to approximately 693 million individuals worldwide (2). This metabolic ailment is intricately linked with numerous complications, notably atherosclerosis, which entails the accumulation of fibro-

Journal of Health and Rehabilitation Research 2791-156X JHRR

fatty plaques within arterial walls, subsequently precipitating the arteries' hardening and narrowing. Such pathophysiological changes are pivotal in the onset of cardiovascular diseases, including heart attacks and strokes, which remain the predominant causes of morbidity and mortality globally (3). The multifactorial genesis of atherosclerosis is underscored by various risk factors such as dyslipidemia, hypertension, obesity, smoking, and notably, diabetes itself (4).

In response to these challenges, conventional therapeutic strategies have predominantly revolved around lifestyle modifications, including the adoption of a balanced diet and regular physical exercise, complemented by pharmacological interventions like oral hypoglycemic agents and insulin therapy (5-7). Nonetheless, there has been a burgeoning interest in exploring the therapeutic potentials of dietary polyphenols, namely catechins, capsaicin, and gingerol. These natural compounds, found in specific food sources, have garnered attention for their anti-inflammatory, anti-diabetic, and anti-atherosclerotic properties. They are known to enhance insulin sensitivity, ameliorate oxidative stress, and mitigate inflammatory responses, thereby offering a promising avenue for managing diabetes and atherosclerosis (9). However, it's critical to acknowledge that the bioavailability and metabolic processing of these compounds can exhibit considerable interindividual variability, potentially influencing their therapeutic efficacy. This variability underscores the importance of personalized approaches in utilizing these natural compounds effectively, taking into account factors such as genetic predispositions, gut microbiota composition, and concurrent medication use.

In light of these considerations, this review endeavors to critically assess the extant body of literature concerning the effects of catechins, capsaicin, and gingerol on diabetes management and atherosclerosis risk reduction. Given the complex interplay between genetic, environmental, and lifestyle factors in the pathogenesis and progression of these conditions, a nuanced understanding of how these dietary polyphenols can be optimized to confer maximal health benefits is paramount. Further research is imperative to unravel the precise mechanisms through which these compounds exert their effects, paving the way for tailored dietary recommendations that could complement existing therapeutic modalities in the battle against diabetes and its cardiovascular complications.

MATERIAL AND METHODS

The comprehensive literature review on the impact of catechins, capsaicin, and gingerol in managing diabetes and reducing the risk of atherosclerosis was meticulously designed to address the research question: How do dietary polyphenols, specifically catechins, capsaicin, and gingerol, influence the management of diabetes mellitus and the risk of developing atherosclerosis? To explore this inquiry, the authors embarked on a systematic search strategy across several databases, including PubMed, Scopus, Web of Science, and Google Scholar, with an additional foray into specialized databases that encompass studies at the intersection of healthcare and zoology, recognizing the potential of animal models in elucidating the mechanisms of action of these compounds (7).

The search strategy was carefully crafted to include a combination of keywords and MeSH terms related to "catechins," "capsaicin," "gingerol," "diabetes mellitus," "atherosclerosis," "polyphenols," and "cardiovascular diseases," among others. The time frame for the literature search was set from the inception of each database until December 2022, to ensure a comprehensive collection of relevant studies. The inclusion criteria were defined to encompass peer-reviewed articles that reported on the effects of catechins, capsaicin, and gingerol on diabetes management and atherosclerosis risk, including both human and animal studies, to draw insights from a broad spectrum of biological contexts. Exclusion criteria were applied to filter out studies that did not directly assess the outcomes of interest, review articles, and non-English language publications, aiming to maintain a focus on primary research and ensure the clarity and accessibility of the synthesized evidence (8).

The evidence synthesis was conducted through a meticulous evaluation of the selected studies, employing both qualitative and quantitative approaches as appropriate. This involved extracting data on study design, participant characteristics, dosage and form of catechins, capsaicin, and gingerol administered, outcomes related to diabetes management and atherosclerosis risk reduction, and the underlying mechanisms of action as reported by the authors. The quality of the included studies was assessed using standardized tools relevant to each study design, such as the Cochrane risk of bias tool for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. This rigorous process allowed for a critical appraisal of the evidence, facilitating a nuanced understanding of the potential benefits and limitations of incorporating these dietary polyphenols into strategies for the management of diabetes and the prevention of atherosclerosis. Through this comprehensive review, the authors aimed to contribute valuable insights to the ongoing discussion on the role of natural compounds in chronic disease management and prevention, highlighting areas for future research and potential applications in clinical practice (9).

FINDINGS AND DISCUSSION

Diabetes mellitus (DM) emerges through one of two fundamental pathophysiological mechanisms: an insufficient secretion of insulin or a reduction in insulin action, known as insulin resistance, which typically triggers a compensatory response of hyperinsulinemia

Journal of Health and Rehabilitation Research 2791-156X JHRR

to maintain normoglycemia (10). This state of insulin resistance, which can be precipitated by genetic predispositions, environmental factors, or a combination thereof, leads to an inability of insulin-sensitive tissues to adequately respond to insulin, culminating in hyperglycemia (11). The complex interplay between these factors underscores the multifaceted nature of diabetes pathogenesis (12).

The development of atherosclerosis, a condition characterized by the stiffening and fatty degeneration of arteries as described by Marchand, follows a distinct yet related pathogenic pathway (13). The disease is marked by the patchy thickening of the arterial sub-intima within medium and large arteries, affecting the arterial lumen and potentially any arterial bed. The variability in the causes, consequences, and management of atherosclerosis across different vascular beds highlights the complexity of this condition (14). The initiation of atherosclerosis is signified by the formation of fatty streaks, resulting from the accumulation of lipid-laden foam cells within the intimal layer of arteries. This can progress to significant lipid accumulation, leading to thrombotic events following endothelial denudation or plaque rupture. The atherosclerotic lesion comprises cellular components (mainly macrophages and smooth muscle cells), extracellular lipid and connective tissue matrix, and intracellular lipid accumulation within macrophages, leading to their transformation into foam cells (15).

The role of catechins in diabetes management has been substantiated through various clinical and epidemiological studies, which have demonstrated their potential in reducing the risk of chronic diseases such as cardiovascular diseases (CVD) (16). Epigallocatechin gallate (EGCG) from green tea, in particular, has shown promise in regulating blood sugar levels through both human and animal studies, by reducing oxidative stress and the production of proinflammatory cytokines, thus mitigating the adverse effects of diabetes (17-20). Specific trials have revealed the efficacy of catechin-rich beverages in significantly lowering insulin levels in individuals with type 2 diabetes, although changes in glycosylated hemoglobin or fasting glucose levels were not universally observed (21). Further research has shown that supplementation with green tea extract containing high levels of EGCG can lead to substantial reductions in fasting insulin, insulin resistance, and glycated hemoglobin levels in obese individuals with type 2 diabetes (22). Studies on animal models, such as Sprague Dawley rats, have further supported the beneficial effects of catechins and EGCG on cholesterol, LDL levels, and blood glucose levels, underscoring their potential in diabetes management (23,24).

In the context of atherosclerosis, disturbances in fatty acid metabolism resulting from type 2 diabetes have been implicated in the development of dyslipidemia, a key contributor to cardiovascular disease and atherosclerosis (25-27). Addressing dyslipidemia in diabetic patients is thus critical for preventing cardiovascular complications (28). Research indicates that green tea, rich in catechins, can improve lipid profiles and vascular function by reducing levels of oxidized LDL and other lipid peroxidation byproducts such as MDA (29-31). Clinical trials and studies have demonstrated the ability of green tea extract supplementation to significantly lower non-HDL, LDL, and total cholesterol levels, as well as reduce total cholesterol, pancreatic lipase levels, serum triglycerides, and LDL-C after consumption, highlighting its potential as a safe and effective treatment for enhancing lipid profiles in postmenopausal women and other populations (32,33).

Recent studies on capsaicin have also shed light on its effects on insulin and glucose levels, further contributing to the understanding of its role in diabetes management (34). Investigations into the consumption of capsaicin have shown increased energy expenditure and activation of brown adipose tissue, decreased plasma glucose levels, and increased insulin levels following intake, indicating its potential in modulating glucose metabolism and insulin sensitivity (35-37). Additionally, research involving healthy participants consuming capsaicin demonstrated a reduction in postprandial hyperinsulinemia, suggesting its utility in managing glucose and insulin responses (38).

Capsaicin, recognized for its potential in weight management through the enhancement of sympathetic nervous system activity, thus reducing hunger and increasing energy expenditure and fat oxidation, has been posited as beneficial for cardiovascular health (39). This compound, by activating the transient receptor potential vanilloid 1 (TRPV1), has been implicated in the reduction of heart microvascular damage, a crucial aspect in the management of atherosclerosis. Studies have demonstrated that capsaicin treatment can mitigate heart microvascular damage and the mortality of cardiac microvascular endothelial cells induced by high-fat, high-glucose diets by modulating Ca2+ concentration and TRPV1 expression in these cells (40). Furthermore, oral administration of capsaicin has been shown to decrease obesity in animal models through a TRPV1-dependent mechanism, suggesting its utility in managing obesity-related cardiovascular risks (41). In vivo studies have further elucidated that dietary capsaicin can ameliorate endothelial dysfunction, a key predictor of atherosclerosis, thereby underscoring its therapeutic potential in cardiovascular disease prevention (42).

Gingerol, a major bioactive component of ginger, has been identified for its potent anti-inflammatory effects, primarily attributed to 6-gingerol, the most abundant compound in ginger extracts (43,44). Its capability to suppress tumor promotion and exert immunosuppressive effects by inhibiting the activation of p38 MAPK and NF κB pathways has been observed, leading to reduced TNF-α expression, inflammation, and COX-2 production (45-47). Additionally, gingerol has been shown to enhance glucose uptake,

insulin sensitivity, and adipocyte differentiation in mouse models, suggesting its beneficial role in improving diabetic conditions (48). Although clinical studies on gingerol's efficacy in diabetes management are limited, emerging research indicates its potential in reducing cholesterol and eicosanoid levels, with doses ranging from 100 milligrams to 3 grams (49). Clinical trials have further demonstrated that ginger supplementation can significantly improve insulin sensitivity and lower levels of insulin, HOMA index, haemoglobin A1C, prostaglandin E2, and C-reactive protein in diabetic patients (50,51). However, the impact of ginger on fasting plasma glucose (FPG) and HbA1C levels has shown variability, indicating the need for extended research to ascertain its full therapeutic potential (52,53).

In the realm of atherosclerosis management, ginger extracts, due to their lipid-lowering, antioxidant, anti-inflammatory, and cardio-protective properties, have been proposed as an effective intervention for preventing the onset and progression of coronary atherosclerosis (54,55). Animal studies incorporating ginger into high-fat diets have shown significant improvements in glucose tolerance, insulin levels, and reductions in cholesterol, triacylglycerol, and blood glucose levels, alongside correction of diabetic proteinuria (56,57). The inclusion of 6-gingerol in diets has been associated with marked reductions in fatty acid oxidation and cholesterol metabolism alterations, thereby mitigating body weight gain and adiposity in high-fat diet-induced obesity models (58). Additionally, ginger extract has been found to influence intra- and extra-mitochondrial enzyme activities, further reducing blood glucose levels in diabetic rats (59). Clinical studies have corroborated these findings, demonstrating ginger's efficacy in lowering triglyceride, cholesterol, LDL, and VLDL levels in patients with hyperlipidemia (60). Moreover, research in animal models has revealed that ginger supplementation can significantly reduce the area of atherosclerotic lesions, providing macroscopic evidence of its beneficial effects on cardiovascular health (61).

CONCLUSION

The exploration of capsaicin and gingerol in the management of diabetes and atherosclerosis reveals significant therapeutic potential, underscoring the importance of integrating natural compounds into comprehensive treatment strategies. These findings suggest that capsaicin and gingerol can contribute to weight management, improve cardiovascular health, and enhance glucose and lipid metabolism, which are crucial in managing and preventing diabetes and atherosclerosis. The health care implications of this research highlight the need for further clinical trials to establish definitive therapeutic guidelines and dosages, potentially leading to the development of novel dietary recommendations and pharmacological interventions that harness the benefits of these natural compounds in combating chronic metabolic and cardiovascular diseases.

REFERENCES

1. Mukhtar, Y., Galalain, A., & Yunusa, U. (2020). A modern overview on diabetes mellitus: a chronic endocrine disorder. European Journal of Biology, 5(2), 1-14.
2. Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. I. D. F. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice, 138, 271-281.
3. La Sala, L., Prattichizzo, F., & Ceriello, A. (2019). The link between diabetes and atherosclerosis. European journal of preventive cardiology, 26(2_suppl), 15-24.
4. Singh, R. B., Mengi, S. A., Xu, Y. J., Arneja, A. S., & Dhalla, N. S. (2002). Pathogenesis of atherosclerosis: A multifactorial process. Experimental & Clinical Cardiology, 7(1), 40.
5. Borse, S. P., Chhipa, A. S., Sharma, V., Singh, D. P., & Nivsarkar, M. (2021). Management of type 2 diabetes: current strategies, unfocussed aspects, challenges, and alternatives. Medical Principles and Practice, 30(2), 109-121.
6. Raveendran, A. V., Chacko, E. C., & Pappachan, J. M. (2018). Non-pharmacological treatment options in the management of diabetes mellitus. European endocrinology, 14(2), 31.
7. Khursheed, R., Singh, S. K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., ... & Dua, K. (2019). Treatment strategies against diabetes: Success so far and challenges ahead. European journal of pharmacology, 862, 172625.
8. Choudhury, H., Pandey, M., Hua, C. K., Mun, C. S., Jing, J. K., Kong, L., ... & Kesharwani, P. (2018). An update on natural compounds in the remedy of diabetes mellitus: A systematic review. Journal of traditional and complementary medicine, 8(3), 361-376.
9. Cruz-Aldaco, K., Santos-Basurto, M. A., Belmares-Cerda, R. E., & Loredo-Treviño, A. (2024). Nutritional Profile of Fermented Food and Their Health Benefits. In The Role of Nutrition in Integral Health and Quality of Life (pp. 107-139). Apple Academic Press.

Journal of Health and Rehabilitation Research 2791-156X JHRR

10. Sen S, Chakraborty R, De B. Diabetes mellitus in 21st century. Singapore:: Springer; 2016 Jul 25. Elsherief WM, Aljarrari AM. Serum Testosterone Levels and Statin Therapy in type two Diabetic and Hypertensive Libyan Male Subjects (Doctoral dissertation, University of Benghazi).
11. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological reviews. 2018 Aug 1.
12. Singh P, Jain P, Pandey R, Shukla SS. Phytotherapeutic review on diabetes Diabette fitoterapinin yeri.
13. Park, J. B., & Avolio, A. (2023). Arteriosclerosis and atherosclerosis assessment in clinical practice: Methods and significance. Pulse, 11(1), 1-8.
14. Jung YS, Shin MH, Kim IS, Kweon SS, Lee YH, Kim OJ, Kim YJ, Chung HJ, Kim OS. Relationship between periodontal disease and subclinical atherosclerosis: The Dong-gu study. Journal of clinical periodontology. 2014 Mar;41(3):262-8.
15. Crowther MA. Pathogenesis of atherosclerosis. ASH Education Program Book. 2005 Jan 1;2005(1):436-41.
16. Anandh Babu PV, Liu D. Green tea catechins and cardiovascular health: an update. Current medicinal chemistry. 2008 Aug 1;15(18):1840-50.
17. Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, Weber P. Epigallocatechin gallate supplementation alleviates diabetes in rodents. The Journal of nutrition. 2006 Oct 1;136(10):2512-8.
18. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. Journal of the American College of Nutrition. 2007 Aug 1;26(4):373S-88S.
19. Crespy V, Williamson G. A review of the health effects of green tea catechins in in vivo animal models. The Journal of nutrition. 2004 Dec 1;134(12):3431S-40S.
20. Schmidt M, Schmitz HJ, Baumgart A, Guedon D, Netsch MI, Kreuter MH, Schmidlin CB, Schrenk D. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food and Chemical Toxicology. 2005 Feb 1;43(2):307-14.
21. Nagao T, Meguro S, Hase T, Otsuka K, Komikado M, Tokimitsu I, Yamamoto T, Yamamoto K. A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes. Obesity. 2009 Feb;17(2):310-7.
22. Hua C, Liao Y, Lin S, Tsai T, Huang C, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebocontrolled clinical trial. Alternative Medicine Review. 2011 Jun;16(2):157-63.
23. Ahmad RS, Butt MS, Sultan MT, Mushtaq Z, Ahmad S, Dewanjee S, De Feo V, Zia-Ul-Haq M. Preventive role of green tea catechins from obesity and related disorders especially hypercholesterolemia and hyperglycemia. Journal of translational medicine. 2015 Dec;13(1):1-9.
24. Hosoda K, Wang MF, Liao ML, Chuang CK, Iha M, Clevidence B, Yamamoto S. Antihyperglycemic effect of oolong tea in type 2 diabetes. Diabetes care. 2003 Jun 1;26(6):1714-8.
25. Park BK, Lee EA, Kim HY, Lee JC, Kim KS, Jeong WH, Kim KY, Ku BJ, Rhee SD. Fatty liver and insulin resistance in the liver-specific knockout mice of mitogen inducible gene-6. Journal of diabetes research. 2016 Oct;2016.
26. Ghaffarzad A, Amani R, Sadaghiani MM, Darabi M, Cheraghian B. Correlation of serum lipoprotein ratios with insulin resistance in infertile women with polycystic ovarian syndrome: a case control study. International Journal of Fertility & Sterility. 2016 Apr;10(1):29.
27. Srikanth S, Deedwania P. Management of dyslipidemia in patients with hypertension, diabetes, and metabolic syndrome. Current hypertension reports. 2016 Oct;18:1-0.
28. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA cardiology. 2017 Apr 1;2(4):370-80.
29. Gutiérrez-Salmeán G, Meaney E, Lanaspa MA, Cicerchi C, Johnson RJ, Dugar S, Taub P, Ramírez-Sánchez I, Villarreal F, Schreiner G, Ceballos G. A randomized, placebo-controlled, double-blind study on the effects of (−)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects. International journal of cardiology. 2016 Nov 15;223:500-6.
30. Tinahones FJ, Rubio MA, Garrido-Sanchez L, Ruiz C, Gordillo E, Cabrerizo L, Cardona F. Green tea reduces LDL oxidability and improves vascular function. Journal of the American College of Nutrition. 2008 Apr 1;27(2):209-13.
31. Yin ST, Tang ML, Su L, Chen L, Hu P, Wang HL, Wang M, Ruan DY. Effects of Epigallocatechin-3-gallate on lead-induced oxidative damage. Toxicology. 2008 Jul 10;249(1):45-54.
32. Samavat H, Newman AR, Wang R, Yuan JM, Wu AH, Kurzer MS. Effects of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial. The American journal of clinical nutrition. 2016 Dec 1;104(6):1671-82.

33. Koutelidakis AE, Rallidis L, Koniari K, Panagiotakos D, Komaitis M, Zampelas A, Anastasiou-Nana M, Kapsokefalou M. Effect of green tea on postprandial antioxidant capacity, serum lipids, C-reactive protein and glucose levels in patients with coronary artery disease. European journal of nutrition. 2014 Mar;53:479-86.

34. Zhang S, Ma X, Zhang L, Sun H, Liu X. Capsaicin reduces blood glucose by increasing insulin levels and glycogen content better than capsiate in streptozotocin-induced diabetic rats. Journal of agricultural and food chemistry. 2017 Mar 22;65(11):2323-30.

35. Yoneshiro T, Aita S, Kawai Y, Iwanaga T, Saito M. Nonpungent capsaicin analogs (capsinoids) increase energy expenditure through the activation of brown adipose tissue in humans. The American journal of clinical nutrition. 2012 Apr 1;95(4):845-50.

36. Weerapan Khovidhunkit M. Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J Med Assoc Thai. 2009;92(1):108-3.

37. Dömötör A, Szolcsányi J, Mózsik G. Capsaicin and glucose absorption and utilization in healthy human subjects. European journal of pharmacology. 2006 Mar 18;534(1-3):280-3.

38. Ahuja KD, Robertson IK, Geraghty DP, Ball MJ. Effects of chili consumption on postprandial glucose, insulin, and energy metabolism. The American journal of clinical nutrition. 2006 Jun 1;84(1):63-9.

39. YOSHIOKA M, LIM K, KIKUZATO S, KIYONAGA A, TANAKA H, SHINDO M, SUZUKI M. Effects of red-pepper diet on the energy metabolism in men. Journal of nutritional science and vitaminology. 1995;41(6):647-56.

40. Ives SJ, Park SY, Kwon OS, Gifford JR, Andtbacka RH, Hyngstrom JR, Richardson RS. TRPV1 channels in human skeletal muscle feed arteries: Implications for vascular function. Experimental physiology. 2017 Sep 1;102(9):1245-58.

41. Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ, Zhao ZG, Zhu SJ, Schrader M. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circulation research. 2007 Apr 13;100(7):1063-70.

42. Xiong S, Wang P, Ma L, Gao P, Gong L, Li L, Li Q, Sun F, Zhou X, He H, Chen J. Ameliorating endothelial mitochondrial dysfunction restores coronary function via transient receptor potential vanilloid 1–mediated protein kinase A/uncoupling protein 2 pathway. Hypertension. 2016 Feb;67(2):451-60.

43. Ojewole JA. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) rhizomes (Zingiberaceae) in mice and rats. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2006 Sep;20(9):764-72.

44. Jiang H, Xie Z, Koo HJ, McLaughlin SP, Timmermann BN, Gang DR. Metabolic profiling and phylogenetic analysis of medicinal Zingiber species: Tools for authentication of ginger (Zingiber officinale Rosc.). Phytochemistry. 2006 Aug 1;67(15):1673-85.

45. Lu J, Guan S, Shen X, Qian W, Huang G, Deng X, Xie G. Immunosuppressive activity of 8-gingerol on immune responses in mice. Molecules. 2011 Mar 22;16(3):2636-45.

46. Kim SO, Kundu JK, Shin YK, Park JH, Cho MH, Kim TY, Surh YJ. [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-κB in phorbol ester-stimulated mouse skin. Oncogene. 2005 Apr;24(15):2558-67.

47. Surh YJ, Park KK, Chun KS, Lee LJ, Lee E, Lee SS. Anti-tumor-promoting activities of selected pungent phenolic substances present in ginger. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer. 1999 Jan 1;18(2):131-9.

48. Sekiya K, Ohtani A, Kusano S. Enhancement of insulin sensitivity in adipocytes by ginger. Biofactors. 2004 Jan 1;22(1-4):153-6.

49. Yu Y, Zick S, Li X, Zou P, Wright B, Sun D. Examination of the pharmacokinetics of active ingredients of ginger in humans. The AAPS journal. 2011 Sep;13:417-26.

50. Arablou T, Aryaeian N, Valizadeh M, Sharifi F, Hosseini A, Djalali M. The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus. International journal of food sciences and nutrition. 2014 Jun 1;65(4):515-20.

51. Mahluji S, Attari VE, Mobasseri M, Payahoo L, Ostadrahimi A, Golzari SE. Effects of ginger (Zingiber officinale) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients. International journal of food sciences and nutrition. 2013 Sep 1;64(6):682-6.

52. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins, leukotrienes and essential fatty acids. 1997 May 1;56(5):379-84.

53. Mozaffari-Khosravi H, Talaei B, Jalali BA, Najarzadeh A, Mozayan MR. The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Complementary therapies in medicine. 2014 Feb 1;22(1):9-16.

Journal of Health and Rehabilitation Research 2791-156X JHRR

54. Setorki M, Nazari B, Asgary S, Azadbakht L, Rafieian-Kopaei M. Anti atherosclerotic effects of verjuice on hypocholesterolemic rabbits. Afr J Pharm Pharmacol. 2011 Aug 1;5(8):1038-45.

55. Shukla Y, Singh M. Cancer preventive properties of ginger: a brief review. Food and chemical toxicology. 2007 May 1;45(5):683-90.

56. Islam MS, Choi H. Comparative effects of dietary ginger (Zingiber officinale) and garlic (Allium sativum) investigated in a type 2 diabetes model of rats. Journal of medicinal food. 2008 Mar 1;11(1):152-9.

57. Al-Amin ZM, Thomson M, Al-Qattan KK, Peltonen-Shalaby R, Ali M. Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. British journal of nutrition. 2006 Oct;96(4):660-6.

58. Beattie JH, Nicol F, Gordon MJ, Reid MD, Cantlay L, Horgan GW, Kwun IS, Ahn JY, Ha TY. Ginger phytochemicals mitigate the obesogenic effects of a high-fat diet in mice: A proteomic and biomarker network analysis. Molecular nutrition & food research. 2011 Sep;55(S2):S203-13.

59. Ramudu SK, Korivi M, Kesireddy N, Lee LC, Cheng IS, Kuo CH, Kesireddy SR. Nephro-protective effects of a ginger extract on cytosolic and mitochondrial enzymes against streptozotocin (STZ)-induced diabetic complications in rats. Chin J Physiol. 2011 Apr 30;54(2):79-86.

60. Alizadeh-Navaei R, Roozbeh F, Saravi M, Pouramir M, Jalali F, Moghadamnia AA. Investigation of the effect of ginger on the lipid levels. Saudi Med J. 2008;29(9):1280-4.

61. Rouhi-Boroujeni H, Gharipour M, Asadi-Samani M, Rouhi-Boroujeni H. The protective effects of ginger on the development of coronary atherosclerosis: An experimental animal study. Der Pharmacia Lettre. 2016;8(3):105-9.